The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600–mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.
 
Michael Weichenthal
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Novartis (Inst)
 
Inge Marie Svane
Stock and Other Ownership Interests - IO Biotech
Honoraria - BMS; IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; Sanofi/Aventis; TILT Biotherapeutics
Consulting or Advisory Role - IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; TILT Biotherapeutics
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); IO Biotech (Inst); Lytix Biopharma (Inst); TILT Biotherapeutics (Inst)
Travel, Accommodations, Expenses - MSD; Novartis; Pfizer
 
Lidija Kandolf Sekulovic
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; MSD Oncology; Novartis; Roche
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; Janssen; MSD Oncology; Novartis; Roche
Travel, Accommodations, Expenses - MSD Oncology; Roche
 
Joanna Mangana
Consulting or Advisory Role - Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - BMS (Inst); MSD (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Pierre Fabre
 
Peter Mohr
Honoraria - Beiersdorf; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
 
Ivan Marquez-Rodas
Consulting or Advisory Role - Amgen; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Incyte; Merck Serono; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi
Travel, Accommodations, Expenses - Bioncotech; Bristol-Myers Squibb; MSD; Roche
 
Henrik Schmidt
Research Funding - MSD
 
Dimitrios C. Ziogas
No Relationships to Disclose
 
Marc Bender
Stock and Other Ownership Interests - Affimed Therapeutics; BioNTech
 
Eva Ellebaek
Honoraria - Bristol Myers Squibb Foundation; Pierre Fabre
Travel, Accommodations, Expenses - Merck
Other Relationship - Novartis
 
Kristina Urch
No Relationships to Disclose
 
Gergana Shalamanova-Deleva
No Relationships to Disclose
 
Iva Gavrilova
No Relationships to Disclose
 
Enrique Espinosa
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - MSD Oncology
Research Funding - Roche (I)
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Dirk Schadendorf
Honoraria - 4SC; Amgen; Array BioPharma; Bristol-Myers Squibb; Daiichi Sankyo Japan; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; Nektar; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Lars Bastholt
No Relationships to Disclose